[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-356787-105":53,"doc-detail-356787-en":127},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":120,"head_meta":122,"extra_data":124,"updated_unix":126},105,"en","medical-science-liaisons-a-key-to-driving-patient-access-to-new-therapies","Medical Science Liaisons - A key to driving patient access to new therapies","","Medical Science Liaisons (MSLs) are therapeutic specialists with advanced scientific training who connect clinical development with commercial success by building compliant, credible relationships with external healthcare experts. The paper explains why MSL growth accelerates across Europe and the U.S., driven by increasingly complex biopharma portfolios and personalized medicines. It outlines the MSL role across the product lifecycle, deployment do’s and don’ts, and key factors for effective MSL teams, including tool support and stakeholder engagement.",{"@graph":63,"@context":119},[64,80,102],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":11,"@type":70,"position":76},"https://docshare.wps.com/template/presentations/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/medical-science-liaisons-a-key-to-driving-patient-access-to-new-therapies/356787/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/medical-science-liaisons-a-key-to-driving-patient-access-to-new-therapies/356787.png","ImageObject",442,249,{"name":88,"@type":89},"Mia  ","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":98,"interactionType":99,"userInteractionCount":101},"InteractionCounter",{"@type":100},"ViewAction",6,{"@type":103,"mainEntity":104},"FAQPage",[105,111,115],{"name":106,"@type":107,"acceptedAnswer":108},"What drives the growth of Medical Science Liaisons (MSLs) in Europe and the U.S.?","Question",{"text":109,"@type":110},"MSL growth is driven by the need to communicate increasingly complex scientific information as biopharma portfolios change and personalized medicines develop, especially in oncology and autoimmune disorders.","Answer",{"name":112,"@type":107,"acceptedAnswer":113},"What is the primary role of MSLs within Medical Affairs?",{"text":114,"@type":110},"MSLs act as a credible bridge to external stakeholders, building relationships with experts in shared therapeutic categories and helping connect clinical development communication to commercial success.",{"name":116,"@type":107,"acceptedAnswer":117},"Why is compliant deployment critical for effective MSL teams?",{"text":118,"@type":110},"The paper emphasizes that the key to productive MSL deployment is ensuring MSLs engage only in legitimate medical projects and execute them in a compliant way to provide high-quality support for all stakeholders.","https://schema.org",{"og:url":78,"og:type":121,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":123,"canonical":78},"index,follow",{"doc_id":125,"site_id":56},356787,1791739223,{"code":4,"msg":5,"data":128},{"doc_id":125,"user_id":129,"nickname":88,"user_avatar":130,"doc_module":9,"category_id":8,"category_name":11,"doc_title":59,"doc_description":61,"doc_content":131,"file_id":132,"file_url":133,"file_type":134,"file_size":135,"view_count":101,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":136,"language":137,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":138,"faqs":139,"seo_title":140,"seo_description":61,"update_tm":141,"read_time":142},687207024478,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","White  \npaper  \nMedical Science Liaisons:  \nA key to driving patient access to new therapies  \nPeter Rutherford, M.D., Ph.D. , Vice President, Integrated Market Access, QuintilesIMS  \nNicola J. Smith, Senior Director, Regional Head of Operations, Field Medical Affairs Projects, QuintilesIMS  \n| TABLE OF CONTENTS |  |\n| --- | --- |\n| Executive summary\u003Cbr>What is an MSL?\u003Cbr>How MSLs differ from other team members\u003Cbr>The MSL role throughout the product lifecycle\u003Cbr>MSL deployment: Do’s and don’ts\u003Cbr>Critical factors in deploying effective MSL teams\u003Cbr>Providing MSLs with tools to support effective engagement\u003Cbr>Advantages of partnering for Medical Affairs deployment Case studies\u003Cbr>Why QuintilesIMS?\u003Cbr>Conclusion\u003Cbr>References\u003Cbr>About the authors | 3\u003Cbr>4\u003Cbr>5\u003Cbr>7\u003Cbr>8\u003Cbr>10\u003Cbr>11\u003Cbr>12\u003Cbr>13\u003Cbr>15\u003Cbr>17\u003Cbr>18\u003Cbr>19 |\n\nExecutive summary  \nBackground: Factors behind the rise of MSLs in Europe and the U.S.  \nThe growth in Medical Science Liaisons (MSLs) is being driven by the need to communicate increasingly complex scientific information associated with changing biopharma product portfolios and the development of personalized medicines with new modes of action, particularly for oncology and autoimmune disorders. As a key member of the Medical Affairs team – which acts as a scientific partner for healthcare stakeholders – MSLs provide a credible link to external stakeholders to act as a demand generator, helping bridge the communication between clinical development and commercial success. The key to productive MSL deployment is to ensure that the MSL team is engaging in legitimate medical projects and is able to execute these projects ina compliant way providing high quality support for all stakeholders.  \nMedical affairs teams must adapt to the complexity involved in building engagement across multiple stakeholders, whose demands are increasing. These include:  \n• Prescribers and healthcare providers requiring faster access to clear medical and scientific data to drive evidence-based decision-making and therapy choices, including knowledge of benefits – as well as risk of adverse events.  \n• Payer/health technology assessment (HTA) bodies demanding clinical trial evidence, health economic and outcomes research (HEOR) findings, comparative effectiveness research, and post-authorization, real-world and safety data to drive decision-making. This is resulting in the need for complex data analysis and the ability to interpret and communicate the associated medical and scientific outputs, ultimately generating higher hurdles for demonstrating product value.  \n• Regulatory authorities demanding adherence with all promotional codes of conduct and monitoring interactions between pharmaceutical companies and healthcare professionals to ensure transparency.  \n• Patients wanting empowerment in their healthcare and demanding access to medical information, participation in decision-making and choice of treatment options.  \nAt the same time, there are increasing challenges in the form of:  \n• More specialized and complex product launches that are highly targeted, requiring education and translation of medical information into practical insights to support clinical decision-making.  \n• Wider healthcare professional engagement is often needed – in addition to prescribing physicians, there may be a need to interact with pathologists and clinical geneticists regarding new biomarkers, for example.  \n• Restricted access to medicines, with austerity measures making it very challenging to convince stakeholders of a product’s value, to enable patient access to expensive medicines.  \n[3](3 | www.quintilesims.com)[ | www.quintilesims.com](3 | www.quintilesims.com)  \nAgainst this challenging backdrop, MSLs have a key role in demonstrating the value of customer-facing medical affairs support:  \n• Engagement and insight: Involvement of scientific opinion leaders in corporate medical activities.  \n• Positioning: MSL and external expert contribution to produc","cbCaidxu1S8JHPvc","https://ap.wps.com/l/cbCaidxu1S8JHPvc","pdf",1112664,20,"English","# Executive summary\n## Background: Factors behind the rise of MSLs in Europe and the U.S.\n# What is an MSL?\n## How MSLs differ from other team members\n## The MSL role throughout the product lifecycle\n# MSL deployment: Do’s and don’ts\n## Critical factors in deploying effective MSL teams\n## Providing MSLs with tools to support effective engagement","[{\"question\":\"What drives the growth of Medical Science Liaisons (MSLs) in Europe and the U.S.?\",\"answer\":\"MSL growth is driven by the need to communicate increasingly complex scientific information as biopharma portfolios change and personalized medicines develop, especially in oncology and autoimmune disorders.\"},{\"question\":\"What is the primary role of MSLs within Medical Affairs?\",\"answer\":\"MSLs act as a credible bridge to external stakeholders, building relationships with experts in shared therapeutic categories and helping connect clinical development communication to commercial success.\"},{\"question\":\"Why is compliant deployment critical for effective MSL teams?\",\"answer\":\"The paper emphasizes that the key to productive MSL deployment is ensuring MSLs engage only in legitimate medical projects and execute them in a compliant way to provide high-quality support for all stakeholders.\"}]","Medical Science Liaisons - A key to driving patient access to new therapies | PDF",1790127285,7]